Advances company’s ambition to provide fully integrated and comprehensive solution for viral vector manufacturing Mirus Bio’s leading GMP transfection reagents complement company’s upstream ...

Viral vector-based cell therapy uses modified viruses to deliver a healthy gene into a cell to treat a disease. The virus’ shell delivers the gene and the vectors, with the genetic information they ...

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, announced the signing of a definitive agreement to acquire Mirus Bio for $600 million. This deal is ...

A global contract developer says it is among the first to offer a standardized approach to manufacturing adeno-associated viruses (AAVs) and lentiviruses (LVVs) for advanced therapies. AGC Biologics ...

Efficient viral vector production is essential for the cost-effective manufacture of cell and gene therapies. Many of the current production workflows are reliant on basal media in batch-mode, which ...

Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, and AGC Biologics, your friendly CDMO expert, have signed a licensing agreement for Asimov’s off-the-shelf ...

Hinnah Campwala (left) is a Principal Scientist in the Cell Biology Development Group at Sartorius BioAnalytical Instruments (Michigan, USA). With a background in drug discovery and immune cell ...

SUZHOU, China, June 25, 2024 /PRNewswire/ -- Porton Advanced recently introduced the MaxCyte cGMP-grade ExPERT GTx Flow Electroporation instrument to its cell therapy platform, marking the company as ...